INO Stock: Inovio’s FDA BLA Milestone, New Equity Offerings and 2026 Catalyst – Latest News and Forecasts (December 7, 2025)

Inovio Pharmaceuticals has quietly turned 2025 into a make‑or‑break year. The small‑cap biotech has completed a Biologics License Application for its lead DNA immunotherapy INO‑3107, raised fresh capital through two stock offerings, and attracted a flurry of new analyst ratings and algorithmic “Strong Buy” labels — all while still burning cash and generating minimal revenue. GuruFocus+3Yahoo Finance+3Stock Titan+3